0001493152-26-011616
SEC filingGenelux Corporation (GNLX), a clinical-stage biopharmaceutical company developing oncolytic viral immunotherapies, reported a net loss of $32.1 million for FY 2025, up 7.6% YoY from $29.9 million in FY 2024, driven by higher operating expenses of $33.2 million versus $31.7 million prior year. Revenue remained negligible at $8K, consistent YoY, from a minor licensing agreement. Research and development expenses rose 4.5% to $19.9 million, primarily due to increased clinical trial costs for the Phase 3 OnPrime/GOG-3076 trial in platinum-resistant ovarian cancer. General and administrative expenses increased 5.3% to $13.4 million, reflecting headcount growth and public company costs. Operating loss widened to $33.2 million from $31.7 million. Other income fell to $1.1 million from $1.8 million, due to lower bond accretion and no gain on accounts payable extinguishment. Balance sheet shows $19.0 million total assets, with $14.6 million in cash equivalents and marketable securities (pro forma $33.1 million post-January 2026 offering), $11.5 million stockholders' equity, amid going concern doubts. Net cash used in operations was $25.3 million. Cash runway extends into Q1 2027, supporting Olvi-Vec trials in ovarian, NSCLC, and SCLC cancers, with topline Phase 3 data expected H2 2026.
Genelux reported FY2025 net loss of $32.1M, worsening 7.6% YoY from $29.9M, amid rising R&D ($19.9M, +4.5%) and G&A ($13.4M, +5.3%) expenses totaling $33.2M versus $31.7M prior year. Revenue flat at $8K from licensing. Operating loss expanded to $33.2M from $31.7M; other income declined to $1.1M from $1.8M. EPS stable at -$1 (37.2M shares). Cash burn intensified with $25.3M operating use versus $21.2M prior. Balance sheet: $19.0M assets, $14.6M liquidity (pro forma $33.1M post-2026 offering), $11.5M equity. Going concern noted due to losses and funding needs.
Revenue minimal at $8K, unchanged YoY, solely from ELIAS Animal Health licensing. No product sales; focus remains preclinical/clinical. No geographic or segment breakdown disclosed.
No gross profit (negligible revenue). Operating margin N/A; loss widened on higher clinical costs (Phase 3 ovarian trial) and headcount. Stock comp $7.6M aided cash flow but pressured P&L.
Operating cash use $25.3M (vs $21.2M YoY), driven by $32.1M loss offset by $7.6M stock comp. Investing provided $12.1M (net securities maturities); financing $9.9M (stock sales). Net cash down $3.2M to $5.3M; total liquidity $14.6M. Assets $19.0M (current $15.1M); liabilities $7.5M; equity $11.5M (accum deficit -$283.5M).
Expect continued losses/expenses for trials (Phase 3 topline H2 2026; NSCLC/SCLC updates 2026). Cash to Q1 2027; need funding via equity/debt/partners. Risks: trial delays, funding, competition. Strategy: advance Olvi-Vec, leverage Newsoara partnership.